CMXC - Cell MedX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.10
0.00 (0.00%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.10
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume3,759
Market Cap4.428M
Beta-0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile2 months ago

    Dr. Terrance Owen Resigns as CEO of Cell MedX Corp

    Carson City, Nevada--(Newsfile Corp. - May 7, 2018) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, effective April 30, 2018, Dr. Terrance Owen resigned from his management and directorship positions with Cell MedX. The resignation of Dr. Owen was not due to ...

  • Newsfile4 months ago

    Cell MedX Corp. Appoints Dr. George Adams as Director

    Carson City, Nevada--(Newsfile Corp. - March 26, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), an early-stage biotech company focusing on the discovery, development and commercialization of products that promote general wellness, is pleased to announce that it has appointed Dr. George Adams to the Board of Directors. "Cell MedX has just completed a clinical trial where it has demonstrated a significant lowering of blood pressure in patients ...

  • Newsfile4 months ago

    Cell MedX Corp. Arranges a Non-Brokered Private Placement Financing

    Carson City, Nevada--(Newsfile Corp. - March 19, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes has arranged a non-brokered private placement offering (the "Offering") set at a price of US$0.10 per Unit for 10,000,000 Units for total gross proceeds of $1,000,000. Each Unit sold under the Offering consists of ...

  • Newsfile6 months ago

    Cell MedX Corp. provides additional information on its observational clinical trial with diabetes and related conditions

    Carson City, Nevada--(Newsfile Corp. - January 30, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), is an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. As reported in a news releases issued by the Company on January 24, 2018, an observational clinical trial was completed by Dr. Richard Tytus and his team at Hamilton Medical ...

  • Newsfile6 months ago

    Cell MedX Corp. Assigned Legal Entity Identifier Number by Deutsche Börse Group

    Carson City, Nevada--(Newsfile Corp. - January 29, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX:MUN), ("Cell MedX" or the "Company"), announces that it has been assigned a Legal Entity Identifier number 967600RJ7LKTH79OWE67. About the Legal Entity Identifier Number ("LEI")The European Union has adopted regulations that require use of the LEI as a barcode equivalent aimed at pinpointing systemic risks. The LEI is a 20-digit alphanumeric code that is an internationally standardized and globally valid ...

  • Newsfile6 months ago

    Cell MedX Corp. completes its first observational clinical trial and observes positive results with diabetes and related conditions

    Carson City, Nevada--(Newsfile Corp. - January 24, 2018) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the observational clinical trial carried out by Dr. Richard Tytus and his team at Hamilton Medical Research Group in Hamilton, Ontario (the "Trial") has been completed. Nutrasource Diagnostics ...

  • Newsfile7 months ago

    Cell MedX Corp. Appoints Dr. Terrance Owen as CEO and Director

    Carson City, Nevada--(Newsfile Corp. - December 5, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has appointed Dr. Terrance Owen to the Board of Directors and as Chief Executive Officer. Dr. Owen replaces Mr. McEnulty, as CEO of the Company. Mr. McEnulty ...

  • Newsfile9 months ago

    Cell MedX Corp. Closes the First Tranche of Its Non-Brokered Private Placement Financing, Converts Debt

    Carson City, Nevada--(Newsfile Corp. - October 19, 2017) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that on October 12, 2017, the Company closed the first tranche of its non-brokered private placement offering (the "Offering") at a price of $0.25 per unit (the "Unit"), by ...

  • Newsfile11 months ago

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - August 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with the corporate update on its current operations. Private PlacementThe Company's board of directors has approved a private placement offering of up to 8,000,000 units of the ...

  • Newsfilelast year

    Cell MedX Corp. Provides Update on its Clinical Observational Trial

    Carson City, Nevada--(Newsfile Corp. - July 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that all 30 subjects taking part in the Company's ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") have ...